uniQure N.V. Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your QURE Investments

By Newsfile

New York, New York--(Newsfile Corp. - October 13, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Happened?

On September 29, 2026, uniQure released 48-month data for ongoing Phase I/II studies of AMT-130, the Company's lead pipeline candidate to treat Huntington's disease. The 48-month data revealed a smaller treatment benefit than the one the Company reported at 36 months. Specifically, AMT-130 showed a "44% slowing of disease progression" at 48 months under the composite Uniform Huntington's Disease Rating Scale, compared to a 75% disease slowing at 36 months. In June, uniQure had announced that the Company intended to submit an application to the FDA to bring AMT-130 to the market and did so on September 2, 2026, submitting a Biologics License Application to the FDA based upon its 36-month data analysis. On the disclosure of the Company's 48-month AMT-130 results, the price of uniQure shares declined by $14.60 per share, or approximately 37.3%, from $39.11 per share on September 28, 2026 to close at $24.51 on September 29, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired uniQure securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP's website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/318852

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.